CN102770125B - 钙泊三醇一水化合物纳米晶体 - Google Patents

钙泊三醇一水化合物纳米晶体 Download PDF

Info

Publication number
CN102770125B
CN102770125B CN201080064526.6A CN201080064526A CN102770125B CN 102770125 B CN102770125 B CN 102770125B CN 201080064526 A CN201080064526 A CN 201080064526A CN 102770125 B CN102770125 B CN 102770125B
Authority
CN
China
Prior art keywords
compositions
particle size
suspension
period
salts monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080064526.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102770125A (zh
Inventor
K·彼得松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CN102770125A publication Critical patent/CN102770125A/zh
Application granted granted Critical
Publication of CN102770125B publication Critical patent/CN102770125B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080064526.6A 2009-12-22 2010-12-22 钙泊三醇一水化合物纳米晶体 Active CN102770125B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK2009000267 2009-12-22
DKPCT/DK2009/000267 2009-12-22
US29309110P 2010-01-07 2010-01-07
US61/293,091 2010-01-07
PCT/DK2010/000183 WO2011076208A2 (en) 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals

Publications (2)

Publication Number Publication Date
CN102770125A CN102770125A (zh) 2012-11-07
CN102770125B true CN102770125B (zh) 2015-02-11

Family

ID=43618145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080064526.6A Active CN102770125B (zh) 2009-12-22 2010-12-22 钙泊三醇一水化合物纳米晶体

Country Status (15)

Country Link
US (2) US20130039952A1 (enExample)
EP (1) EP2515874B1 (enExample)
JP (1) JP5816194B2 (enExample)
CN (1) CN102770125B (enExample)
AU (1) AU2010335655B2 (enExample)
BR (1) BR112012015449B1 (enExample)
CA (1) CA2785253A1 (enExample)
ES (1) ES2523119T3 (enExample)
IL (1) IL220516A (enExample)
MX (1) MX2012007234A (enExample)
NZ (1) NZ601000A (enExample)
PL (1) PL2515874T3 (enExample)
RU (1) RU2555339C2 (enExample)
WO (1) WO2011076208A2 (enExample)
ZA (1) ZA201204618B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918369C (en) * 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
KR20190042558A (ko) 2016-07-05 2019-04-24 크라토스 엘엘씨 부동태화된 예비리튬화된 마이크론 및 서브마이크론 iva족 입자 및 이의 제조방법
US11637280B2 (en) 2017-03-31 2023-04-25 Kratos LLC Precharged negative electrode material for secondary battery
CN108904445A (zh) * 2018-08-06 2018-11-30 江苏知原药业有限公司 钙泊三醇纳米悬浮液
CN109157661B (zh) * 2018-09-10 2021-09-24 南京工业大学 一种配体辅助下用氧化物silica包覆疏水性分子晶体的方法
RU2749360C1 (ru) * 2020-10-09 2021-06-09 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения ладонно-подошвенного пустулеза
JP7751298B2 (ja) * 2021-07-14 2025-10-08 株式会社ツツミプランニング 浸透深さの調整方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015912A1 (en) * 1993-01-15 1994-07-21 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) New crystalline form of a vitamin d analogue
US20050281886A1 (en) * 2004-05-06 2005-12-22 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315787D0 (en) * 1983-06-08 1983-07-13 Briggs J H Coolant spray
US4758432A (en) * 1984-10-15 1988-07-19 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6403654B1 (en) * 2000-04-13 2002-06-11 Mariana De Oliveira Compositions for and method of treatment for psoriasis
PL212660B1 (pl) * 2000-10-27 2012-11-30 Leo Pharma As Zasadniczo niewodna zelowa kompozycja farmaceutyczna do podawania na skóre oraz jej zastosowanie
EP1339390A2 (en) * 2000-12-06 2003-09-03 Pharmacia Corporation Laboratory scale milling process
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
CA2509101A1 (en) 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
CA2530302C (en) 2003-07-24 2013-12-03 Leo Pharma A/S Novel aminobenzophenone compounds
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
ES2341473T3 (es) 2004-12-13 2010-06-21 Leo Pharma A/S Compuestos de aminobenzofenona sustituida con triazol.
ES2447301T3 (es) * 2005-06-01 2014-03-11 Glaxosmithkline Intellectual Property Development Limited Formulación vitamínica
WO2007050543A2 (en) * 2005-10-24 2007-05-03 Collegium Pharmaceutical, Inc. Topical pharmaceutical foam composition
AU2007264418B2 (en) * 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2008058755A1 (en) * 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
HRP20110464T1 (hr) 2006-12-22 2011-07-31 Leo Pharma A/S Supstituirani acetofenoni korisni kao inhibitori pde4
SI2114951T1 (sl) 2007-02-28 2014-08-29 Leo Pharma A/S Novi zaviralci fosfodiesteraze
CN101677979A (zh) 2007-04-19 2010-03-24 利奥制药有限公司 Src家族激酶抑制剂
EP2146780A1 (en) 2007-05-11 2010-01-27 Sonneborn Inc. Petrolatums having silicone-like properties
WO2010069322A1 (en) 2008-12-19 2010-06-24 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015912A1 (en) * 1993-01-15 1994-07-21 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) New crystalline form of a vitamin d analogue
US20050281886A1 (en) * 2004-05-06 2005-12-22 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents

Also Published As

Publication number Publication date
JP5816194B2 (ja) 2015-11-18
AU2010335655A1 (en) 2012-07-19
NZ601000A (en) 2014-07-25
JP2013515019A (ja) 2013-05-02
CA2785253A1 (en) 2011-06-30
BR112012015449B1 (pt) 2021-09-28
ES2523119T3 (es) 2014-11-21
HK1177694A1 (en) 2013-08-30
RU2555339C2 (ru) 2015-07-10
US20140322331A1 (en) 2014-10-30
MX2012007234A (es) 2012-07-30
EP2515874A2 (en) 2012-10-31
CN102770125A (zh) 2012-11-07
US20130039952A1 (en) 2013-02-14
IL220516A (en) 2015-06-30
ZA201204618B (en) 2013-09-25
AU2010335655B2 (en) 2015-03-05
EP2515874B1 (en) 2014-08-20
WO2011076208A2 (en) 2011-06-30
PL2515874T3 (pl) 2015-01-30
RU2012130412A (ru) 2014-01-27
WO2011076208A3 (en) 2012-03-01
BR112012015449A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
CN102770125B (zh) 钙泊三醇一水化合物纳米晶体
JP5873439B2 (ja) ビタミンｄ類似体および溶媒と界面活性剤の混合物を含む皮膚組成物
CN102770121B (zh) 包含溶剂混合物和维生素d衍生物或类似物的药物组合物
CN102770143B (zh) 包含维生素d类似物和共溶剂-表面活性剂混合物的药物组合物
CN108904445A (zh) 钙泊三醇纳米悬浮液
HK1177694B (en) Calcipotriol monohydrate nanocrystals
HK1177696B (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
HK1177899B (en) Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1177694

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1177694

Country of ref document: HK